Patents by Inventor Gregory A. Hawkins
Gregory A. Hawkins has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240126832Abstract: A method comprises receiving a kernel used to convolve with an input tensor. For a first dimension of the kernel, a square block of values for each single dimensional vector of the kernel that includes all rotations of that single dimensional vector is generated. For each additional dimension of the kernel, group blocks of an immediately preceding dimension into sets of blocks, each set of blocks including blocks of the immediately preceding dimension that are aligned along a vector that is parallel to the axis of the dimension; and generate, for the additional dimension, one or more blocks of values, each block including all rotations of blocks within each of the sets of blocks of the immediately preceding dimension. The block of values corresponding to the last dimension in the additional dimensions of the kernel is output as the expanded kernel.Type: ApplicationFiled: October 6, 2023Publication date: April 18, 2024Inventors: Jonathan Alexander Ross, Thomas Hawkins, Gregory Michael Thorson, Matt Boyd
-
Patent number: 11914782Abstract: In some implementations, a computing device can be configured to automatically turn off notifications when generating a notification would cause a disturbance or be unwanted by a user. The device can be configured with quiet hours during which notifications that would otherwise be generated by the computing device can be suppressed. In some implementations, quiet hours can be configured as a time period with a start time and an end time. In some implementations, quiet hours can be derived from application data. For example, calendar data, alarm clock data, map data, etc. can be used to determine when quiet hours should be enforced. In some implementations, the device can be configured with exceptions to quiet hour notification suppression. In some implementations, the user can identify contacts to which the quiet hours notification suppression should not be applied.Type: GrantFiled: February 10, 2023Date of Patent: February 27, 2024Assignee: Apple Inc.Inventors: Imran A. Chaudhri, Gregory Novick, Scott Forstall, Morgan Grainger, George R. Dicker, Tyler Hawkins
-
Publication number: 20170057121Abstract: A carbon/carbon part and processes for making carbon/carbon parts are provided. The process involves inserting a polyacrylonitrile preform (PAN preform) into a furnace, introducing an inert atmosphere into the furnace, and ramping up the furnace to a temperature greater than 1200° C. while maintaining the total pressure in the furnace greater 0.5 Atm. The method may convert the PAN preform into a carbon preform. The carbonization may be completed while maintaining the total pressure in the furnace greater than 0.5 Atm.Type: ApplicationFiled: August 26, 2015Publication date: March 2, 2017Applicant: GOODRICH CORPORATIONInventors: Gregory Hawkins, Diane Main
-
Publication number: 20150070885Abstract: An LED lamp for use in two-by-two light fixtures having coplanar electrical receptacles. The LED lamp is ideal for use as a replacement of fluorescent lamps in existing fluorescent fixtures and is U shaped with electrical connectors at each end. The U shaped elongate tube is made of an outer shell defining a cavity with a PCB mounted therein. The LED elements are mounted on the PCB. The LED lamp does not have coupling connectors enabling it to emit light along the entire axial length of the tube.Type: ApplicationFiled: September 8, 2014Publication date: March 12, 2015Inventors: Alfred Petro, Gregory Hawkins
-
Publication number: 20070185086Abstract: Patients susceptible to or suffering from disorders, such as central nervous system disorders, which are characterized by an alteration in normal neurotransmitter release, such as dopamine release (e.g., Parkinsonism, Parkinson's Disease, Tourette's Syndrome, attention deficient disorder, or schizophrenia), are treated by administering a 1-aza-2-(3-pyridyl)bicyclo[2.2.1]heptane, a 1-aza-2-(3-pyridyl)bicyclo[2.2.2]octane, a 1-aza-2-(3-pyridyl)bicyclo[3.2.1]octane, a 1-aza-2-(3-pyridyl)bicyclo[3.2.2]nonane, a 1-aza-7-(3-pyridyl)bicyclo[2.2.1]heptane, a 1-aza-3-(3-pyridyl)bicyclo[3.2.2]nonane, or a 1-aza-7-(3-pyridyl)bicyclo[3.2.2]nonane. The compounds can exist as individual stereoisomers, racemic mixtures, diastereomers and the like.Type: ApplicationFiled: April 2, 2007Publication date: August 9, 2007Inventors: Merouane Bencherif, Craig Miller, Gregory Hawkins, Balwinder Bhatti
-
Publication number: 20060288931Abstract: A method of creating an air barrier on both sides of an innerliner splice on the inside surface of a green tire when a bladder release lubricant is being applied thereto to prevent contamination of the splice. High pressure air is directed through air nozzles on both sides of the innerliner splice just prior to and during the application of the lubricant. A pressure sensor detects high or low air pressure during the creation of the air barriers to stop the spray of lubricant should either situation be detected.Type: ApplicationFiled: August 31, 2006Publication date: December 28, 2006Applicant: Bridgestone/Firestone North American Tire, LLCInventors: Gregory Hawkins, Dan Shipley
-
Publication number: 20060175259Abstract: According to one aspect of the disclosure, there is provided an apparatus (210) for performing electrochromatography. The apparatus (210) includes a die block (222) which is movable to exert a pressure greater than atmospheric pressure on a chromatography sample plate during performance of an electrochromatography procedure. A method of performing electrochromatography is also disclosed.Type: ApplicationFiled: June 17, 2004Publication date: August 10, 2006Inventors: David Nurok, Robert Santini, Randall Replogle, Gregory Hawkins, Henry Hawkins, James Koers
-
Publication number: 20050282823Abstract: Patients susceptible to or suffering from disorders, such as central nervous system disorders, which are characterized by an alteration in normal neurotransmitter release, such as dopamine release (e.g., Parkinsonism, Parkinson's Disease, Tourette's Syndrome, attention deficient disorder, or schizophrenia), are treated by administering a compound of Formulas 1 or 2, as described herein. The compounds of Formulas 1 and 2 are also useful for treating pain, and treating drug addiction, nicotine addiction, and/or obesity. The compounds can exist as individual stereoisomers, racemic mixtures, diastereomers and the like.Type: ApplicationFiled: October 15, 2004Publication date: December 22, 2005Applicant: TARGACEPT, INC.Inventors: Scott Breining, Balwinder Bhatti, Gregory Hawkins, Lan Miao, Anatoly Mazurov, Teresa Phillips, Craig Miller
-
Patent number: 6828103Abstract: A method of screening a subject for increased likelihood of having a favorable response to estrogen replacement therapy comprises detecting the presence of the rare form of at least one estrogen receptor alpha polymorphism in the subject, the presence of the estrogen receptor alpha polymorphism indicating the subject is more likely to have a favorable response to estrogen replacement therapy (e.g., with respect to cardiovascular health, heart disease, and/or HDL levels).Type: GrantFiled: February 22, 2002Date of Patent: December 7, 2004Assignee: Wake Forest UniversityInventors: David M. Herrington, Timothy D. Howard, Gregory A. Hawkins, Deborah A. Meyers
-
Publication number: 20020187495Abstract: A method of screening a subject for increased likelihood of having a favorable response to estrogen replacement therapy comprises detecting the presence of the rare form of at least one estrogen receptor alpha polymorphism in the subject, the presence of the estrogen receptor alpha polymorphism indicating the subject is more likely to have a favorable response to estrogen replacement therapy (e.g., with respect to cardiovascular health, heart disease, and/or HDL levels).Type: ApplicationFiled: February 22, 2002Publication date: December 12, 2002Inventors: David M. Herrington, Timothy D. Howard, Gregory A. Hawkins, Deborah A. Meyers
-
Patent number: 6048696Abstract: A method of analyzing a DNA molecule is disclosed. In one embodiment the method comprises the steps of exposing a DNA molecule to an effective amount of a chemical modification reagent wherein the reagent converts guanine to 8-hydroxyguanine. The oxidized product is then exposed to a DNA glycosylase enzyme and the DNA molecule is cleaved at the site of the 8-hydroxyguanine. The fragments are then resolved by electrophoresis and the position of guanine residues within the DNA molecule is determined. In a preferred embodiment of the present invention, the modification reagent is a thiazine dye and the enzyme is FPG protein.Type: GrantFiled: May 13, 1998Date of Patent: April 11, 2000Assignee: Epicentre Technologies CorporationInventors: Leslie M. Hoffman, Gregory A. Hawkins
-
Patent number: 5965106Abstract: A method for in-vivo targeting a functional moiety in a patient by administering a targeting moiety coupled to an affinity component, wherein the targeting moiety has affinity for binding sites in a target area, and administering a binding partner to the affinity component coupled to a functional moiety to localize the functional moiety in the target area. Preferably the targeting moiety is an antibody and the functional moiety is a radiometal when performing in vivo imaging or therapy. The affinity component may be a novel methotrexate analog. Preferably, the affinity component is thermo-stabilized.Type: GrantFiled: June 5, 1995Date of Patent: October 12, 1999Assignee: PerImmune Holdings, Inc.Inventors: Nicholas Pomato, Richard P. McCabe, Gregory A. Hawkins, Reinhard Bredehorst, Chong-Ho Kim, Carl-Wilhelm Vogel
-
Patent number: 5578289Abstract: A method for in-vivo targeting a functional moiety in a patient by administering a targeting moiety coupled to an affinity component, wherein the targeting moiety has affinity for binding sites in a target area, and administering a binding partner to the affinity component coupled to a functional moiety to localize the functional moiety in the target area. Preferably the targeting moiety is an antibody and the functional moiety is a radiometal when performing in vivo imaging or therapy. The affinity component may be a novel methotrexate analog.Type: GrantFiled: November 4, 1993Date of Patent: November 26, 1996Assignee: Akzo N.V.Inventors: Nicholas Pomato, Richard P. McCabe, Gregory A. Hawkins, Reinhard Bredehorst, Chong-Ho Kim, Carl-Wilhelm E. Vogel